Media stories about TrovaGene (NASDAQ:TROV) have trended positive this week, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TrovaGene earned a coverage optimism score of 0.26 on Accern’s scale. Accern also gave news headlines about the medical research company an impact score of 45.5463518698921 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the headlines that may have effected Accern Sentiment’s analysis:

Shares of TrovaGene (NASDAQ TROV) opened at 0.71 on Friday. The firm’s 50-day moving average price is $0.86 and its 200 day moving average price is $1.08. The stock’s market cap is $26.46 million. TrovaGene has a 1-year low of $0.61 and a 1-year high of $5.19.

A number of equities research analysts have weighed in on TROV shares. Maxim Group set a $4.00 target price on TrovaGene and gave the company a “buy” rating in a research report on Thursday, May 25th. Cantor Fitzgerald reissued an “overweight” rating on shares of TrovaGene in a research report on Tuesday, August 8th.

ILLEGAL ACTIVITY WARNING: “Favorable Media Coverage Somewhat Unlikely to Affect TrovaGene (TROV) Share Price” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/09/02/favorable-media-coverage-somewhat-unlikely-to-affect-trovagene-trov-share-price.html.

TrovaGene Company Profile

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Insider Buying and Selling by Quarter for TrovaGene (NASDAQ:TROV)

Receive News & Stock Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related stocks with our FREE daily email newsletter.